MENU
+Compare
GRFS
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$10.10
Change
+$0.16 (+1.61%)
Capitalization
5.48B

GRFS Grifols SA Forecast, Technical & Fundamental Analysis

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins... Show more

GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GRFS with price predictions
Jul 25, 2025

GRFS sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for GRFS moved above the 200-day moving average on June 27, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on GRFS as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GRFS just turned positive on July 25, 2025. Looking at past instances where GRFS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 195 cases where GRFS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GRFS moved out of overbought territory on July 22, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where GRFS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GRFS broke above its upper Bollinger Band on July 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.716) is normal, around the industry mean (5.632). P/E Ratio (68.679) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.266) is also within normal values, averaging (3.004). Dividend Yield (0.045) settles around the average of (0.161) among similar stocks. GRFS's P/S Ratio (0.637) is slightly lower than the industry average of (3.643).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GRFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

View a ticker or compare two or three
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GRFS is expected to report earnings to rise 67.24% to 22 cents per share on July 29

Grifols SA GRFS Stock Earnings Reports
Q2'25
Est.
$0.22
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.02
Q3'24
Missed
by $0.04
Q2'24
Est.
$0.09
The last earnings report on May 12 showed earnings per share of 13 cents, missing the estimate of 16 cents. With 784.24K shares outstanding, the current market capitalization sits at 5.48B.
A.I.Advisor
published Dividends

GRFS paid dividends on June 14, 2021

Grifols SA GRFS Stock Dividends
А dividend of $0.46 per share was paid with a record date of June 14, 2021, and an ex-dividend date of June 03, 2021. Read more...
A.I. Advisor
published General Information

General Information

a manufacturer of plasma-derived biological medicines

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Avinguda de la Generalitat, 152
Phone
+34 935712200
Employees
23744
Web
https://www.grifols.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMNGX19.470.12
+0.62%
MassMutual Mid Cap Growth Y
RMBGX37.050.08
+0.22%
RMB I
RWIGX72.500.04
+0.06%
American Funds Capital World Gr&Inc R6
MAILX20.78-0.08
-0.38%
BlackRock International Instl
MLXCX28.37-0.20
-0.70%
Catalyst Energy Infrastructure C

GRFS and Stocks

Correlation & Price change

A.I.dvisor tells us that GRFS and BIIB have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRFS and BIIB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+1.61%
BIIB - GRFS
28%
Poorly correlated
-0.81%
GILD - GRFS
28%
Poorly correlated
+2.65%
GIFOF - GRFS
26%
Poorly correlated
N/A
SNY - GRFS
24%
Poorly correlated
+0.48%
AMRN - GRFS
20%
Poorly correlated
-0.74%
More